FDA Approves Novel Antibiotic Combination Emblaveo for Complex Abdominal Infections
• AbbVie's Emblaveo, a groundbreaking aztreonam-avibactam combination, receives FDA approval for treating complicated intra-abdominal infections with limited treatment options.
• The novel therapy combines a monobactam antibiotic with a β-lactamase inhibitor, effectively targeting resistant Gram-negative bacteria including those producing metallo-β-lactamases.
• Commercial availability is scheduled for Q3 2025, offering healthcare providers a crucial new tool against antimicrobial-resistant pathogens in complicated intra-abdominal infections.
Antabio's MEM-ANT3310 Completes Phase 1 Trial, Showing Promise Against Multidrug-Resistant Infections
• Antabio's MEM-ANT3310, a novel antibacterial combination, has successfully completed its Phase 1 clinical trial in healthy volunteers, demonstrating good tolerability.
• The trial assessed the safety, tolerability, and pharmacokinetics of ANT3310, a serine-beta-lactamase inhibitor, both alone and in combination with meropenem.
• Results indicate that ANT3310 was well-tolerated with no serious adverse events and exhibited compatible pharmacokinetics with meropenem, supporting further patient studies.
• MEM-ANT3310 is designed to combat antimicrobial resistance in severe hospital infections, particularly those caused by Gram-negative pathogens like CRAB, CRE, and Pseudomonas aeruginosa.
© Copyright 2025. All Rights Reserved by MedPath